Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Keiko Murase

Showing results (11-20 of 24) with videos related to

Pageof 3
Sort By:
Breast Cancer Research and Treatment|November 18, 2015
High levels at baseline of serum pyridinoline crosslinked carboxyterminal telopeptide of type I collagen are associated with worse prognosis for breast cancer patientsMichiko Imamura, Arisa Nishimukai, Tomoko Higuchi, et al.
International Journal of Clinical Oncology|July 4, 2013
Influence of body mass index on clinicopathological factors including estrogen receptor, progesterone receptor, and Ki67 expression levels in breast cancersAyako Yanai, Yoshimasa Miyagawa, Keiko Murase, et al.
International Journal of Clinical Oncology|September 15, 2024
Neutrophil-to-lymphocyte ratio at the end of treatment with CDK4/6 inhibitors is an independent prognostic factor for ER-positive HER2-negative advanced breast cancerAyumu Mitsuyoshi, Masayuki Nagahashi, Haruka Kanaoka, et al.
Breast (Edinburgh, Scotland)|August 30, 2016
Prognostic significance of preoperative <sup>18</sup>F-FDG PET/CT for breast cancer subtypesTomoko Higuchi, Arisa Nishimukai, Hiromi Ozawa, et al.
Breast Cancer (Tokyo, Japan)|August 2, 2014
Prognostic significance of geminin expression levels in Ki67-high subset of estrogen receptor-positive and HER2-negative breast cancersTomoko Yagi, Natsuko Inoue, Ayako Yanai, et al.
Anticancer Research|June 4, 2021
Investigation of a Novel S-1 Administration Schedule for Treating Metastatic and Recurrent Breast Cancer (KBCOG13)Mayuko Miki, Shintaro Takao, Muneharu Konishi, et al.
Anticancer Research|October 3, 2022
Absolute Lymphocyte Count Is an Independent Prognostic Factor for ER-positive HER2-negative Advanced Breast Cancer Patients Treated With CDK4/6 InhibitorsHaruka Kanaoka, Masayuki Nagahashi, Yusa Atake, et al.
Clinical Breast Cancer|January 21, 2015
Activation of mTOR/S6K But Not MAPK Pathways Might Be Associated With High Ki-67, ER(+), and HER2(-) Breast CancerAyako Yanai, Natsuko Inoue, Tomoko Yagi, et al.
International Journal of Clinical Oncology|September 5, 2015
Impact of biomarker changes during neoadjuvant chemotherapy for clinical response in patients with residual breast cancersYukie Enomoto, Takashi Morimoto, Arisa Nishimukai, et al.
Breast Cancer (Tokyo, Japan)|August 7, 2013
C4.4A highly expressed in HER2-positive human breast cancers may indicate a good prognosisTomohiro Miyake, Takashi Ito, Ayako Yanai, et al.
Pageof 3

Showing results (11-20 of 24) with videos related to

Sort By:
Pageof 3
Breast Cancer Research and Treatment|November 18, 2015
High levels at baseline of serum pyridinoline crosslinked carboxyterminal telopeptide of type I collagen are associated with worse prognosis for breast cancer patientsMichiko Imamura, Arisa Nishimukai, Tomoko Higuchi, et al.
International Journal of Clinical Oncology|July 4, 2013
Influence of body mass index on clinicopathological factors including estrogen receptor, progesterone receptor, and Ki67 expression levels in breast cancersAyako Yanai, Yoshimasa Miyagawa, Keiko Murase, et al.
International Journal of Clinical Oncology|September 15, 2024
Neutrophil-to-lymphocyte ratio at the end of treatment with CDK4/6 inhibitors is an independent prognostic factor for ER-positive HER2-negative advanced breast cancerAyumu Mitsuyoshi, Masayuki Nagahashi, Haruka Kanaoka, et al.
Breast (Edinburgh, Scotland)|August 30, 2016
Prognostic significance of preoperative <sup>18</sup>F-FDG PET/CT for breast cancer subtypesTomoko Higuchi, Arisa Nishimukai, Hiromi Ozawa, et al.
Breast Cancer (Tokyo, Japan)|August 2, 2014
Prognostic significance of geminin expression levels in Ki67-high subset of estrogen receptor-positive and HER2-negative breast cancersTomoko Yagi, Natsuko Inoue, Ayako Yanai, et al.
Anticancer Research|June 4, 2021
Investigation of a Novel S-1 Administration Schedule for Treating Metastatic and Recurrent Breast Cancer (KBCOG13)Mayuko Miki, Shintaro Takao, Muneharu Konishi, et al.
Anticancer Research|October 3, 2022
Absolute Lymphocyte Count Is an Independent Prognostic Factor for ER-positive HER2-negative Advanced Breast Cancer Patients Treated With CDK4/6 InhibitorsHaruka Kanaoka, Masayuki Nagahashi, Yusa Atake, et al.
Clinical Breast Cancer|January 21, 2015
Activation of mTOR/S6K But Not MAPK Pathways Might Be Associated With High Ki-67, ER(+), and HER2(-) Breast CancerAyako Yanai, Natsuko Inoue, Tomoko Yagi, et al.
International Journal of Clinical Oncology|September 5, 2015
Impact of biomarker changes during neoadjuvant chemotherapy for clinical response in patients with residual breast cancersYukie Enomoto, Takashi Morimoto, Arisa Nishimukai, et al.
Breast Cancer (Tokyo, Japan)|August 7, 2013
C4.4A highly expressed in HER2-positive human breast cancers may indicate a good prognosisTomohiro Miyake, Takashi Ito, Ayako Yanai, et al.
Pageof 3